[go: up one dir, main page]

US4324895A - Novel process for producing pyrimidine nucleosides and novel pyrimidine nucleosides obtained thereby - Google Patents

Novel process for producing pyrimidine nucleosides and novel pyrimidine nucleosides obtained thereby Download PDF

Info

Publication number
US4324895A
US4324895A US05/735,777 US73577776A US4324895A US 4324895 A US4324895 A US 4324895A US 73577776 A US73577776 A US 73577776A US 4324895 A US4324895 A US 4324895A
Authority
US
United States
Prior art keywords
general formula
following general
tetrahydrofuranyl
represented
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US05/735,777
Inventor
Masanao Matsui
Tomoya Ogawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RIKEN
Original Assignee
RIKEN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP50144637A external-priority patent/JPS5268189A/en
Priority claimed from JP18076A external-priority patent/JPS5285178A/en
Priority claimed from JP2783776A external-priority patent/JPS52116483A/en
Priority claimed from JP2783676A external-priority patent/JPS52111581A/en
Priority claimed from JP5346376A external-priority patent/JPS5268190A/en
Application filed by RIKEN filed Critical RIKEN
Application granted granted Critical
Publication of US4324895A publication Critical patent/US4324895A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/22—Tin compounds
    • C07F7/2224—Compounds having one or more tin-oxygen linkages

Definitions

  • the present invention relates to novel pyrimidine nucleosides or 5-halogenouracil substituted on the nitrogen atoms thereof with a 2'-tetrahydrofuranyl radical and a process for producing the same.
  • pyrimidine nucleosides have drawn attention as pharmaceuticals having diversified pharmaceutical effects, for example as an anticancer medicine with excellent therapeutic effect on various types of cancers.
  • pyrimidine nucleosides have become known as an antimetabolic agent in the fields of pharmaceuticals and agricultural chemicals and as a condiment in the food industries.
  • Ftorafur is a derivative of 5-fluorouracil (5-FU) which is bonded, at the N-1 position thereof, with 2-position of tetrahydrofurane residue, and functions as a masked compound which is gradually converted into an active compound such as 5-FU in the blood vessels and internal organs.
  • 5-FU 5-fluorouracil
  • Ftorafur proved to be similarly effective as 5-FU against cancers of the stomach, colon, rectum and other parts of the digestive tract, lung cancer and particularly gland cancers.
  • the total dose required for positive result is 20-40 grams in total with a daily dose of 800-1,200 mgs.
  • Ftorafur in general shows significantly lighter secondary effects than in 5-FU, and causes almost no diarrhoea, perforation, medullary disorders or other serious secondary troubles which frequently occur in the administration of 5-FU. From this standpoint Ftorafur proved to be clinically far superior to 5-FU.
  • the antitumor effect of Ftorafur is particularly marked in breast cancer, and is comparable, in case of cancers of the digestive tract such as stomach cancer, to the effect of 5-FU obtained by intravenous administration. Also in this case, Ftorafur is far superior to 5-FU with respect to the secondary effects.
  • Pyrimidine nucleosides are already known to be synthesizable by means of so-called silicon process or mercury process, most prior reference being devoted to the former process.
  • pyrimidine nucleosides are obtained by reacting bistrimethylsilyl derivative of uracil with acylated sugars or furane derivatives in the presence of Friedel-Crafts catalyst.
  • Japanese Patent Publication No. 8551/1965 published on May 4, 1965 discloses a process for producing pyrimidine nucleosides represented by a general formula: ##STR1## wherein R 3 and R 4 are members selected from hydrogen atom, hydroxyl radical, amino radical, mercapto radical and methyl radical and Y is a glucosyl radical; which comprises reacting a pyrimidine derivative represented by a general formula: ##STR2## wherein R 3 and R 4 have the same meaning as explained above, with a tri-(lower alkyl)-chlorosilane or hexa(lower alkyl)-disilazane in the presence of a tertinary amine and reacting thus obtained reaction product with a halogeno-pentose or a halogeno-hexose.
  • Said mercury process consists of a reaction between monomethylated pyrimidine and a 2-substituted tetrahydrofurane at a low temperature as reported in Doklady Akademii Nauk SSSR 176, No. 2, 332-335(1967) of which English translation was published in DOKLADY CHEMISTRY 176, No. 1-3, 798-801 Sept. (1967).
  • the pyrimidine nucleosides particularly N 1 -(2'-tetrahydrofuryl)-5-fluorouracil known under a name of FT-207 "Fotrafur" and the related compounds thereof, are known to be synthesizable either by said silicon process or by mercury process.
  • said mercury process is disadvantageous in the use of a low-temperature reaction to be effected as low as -40° C. and also in the use of toxic mercury salts.
  • the present invention is based on a tin process utilizing a reaction between a stannylated pyrimidine derivative and a tetrahydrofurane derivative which, avoiding the above-mentioned drawbacks, makes it possible to obtain the desired compound with an elevated yield and at a nearly ambient temperature, and further makes it possible to obtain novel compounds which have not been reported in the prior references.
  • the object of the present invention is to provide a process for producing pyrimidine nucleosides by means of such tin process.
  • An another object of the present invention is to provide a novel process for producing pyrimidine nucleosides wherein 5-halogenouracil is substituted, on a carbon atom thereof, with a tetrahydrofurane residue, by means of said tin process.
  • Still another object of the present invention is to provide a process for producing N 1 -(2'-tetrahydrofuryl)-5-fluorouracil by means of said tin process.
  • Still another object of the present invention is to provide novel pyrimidine nucleosides obtained in connection with the development of said tin process.
  • Still further object of the present invention is to provide novel bis(tri-lower alkylstannyl)-5-halogenouracil.
  • Still another object of this invention is to provide a process for producing the said stannyl uracil derivatives.
  • the present invention is to provide a process for producing pyrimidine nucleosides wherein a tetrahydrofurane reside is bonded to nitrogen atoms of pyrimidine nucleus by reacting a bis(tri-n-lower alkylstannyl)-5-halogenouracil with a 2-substituted tetrahydrofurane, also to provide pyrimidine nucleosides obtained by such process.
  • the bis(tri-n-lower alkylstannyl)-5-halogenouracil which is utilized as a starting material is a novel substance obtained by a reaction between 5-halogenouracil and bis(tri-n-lower alkylstannyl)oxide in a manner as explained in the following.
  • 5-halogenouracil is heated under reflux with equimolar or approximately equimolar amount of bis(trilower alkylstannyl)oxide in the presence of an aprotic solvent such as toluene with continuous elimination of water. After the distillation of water is terminated, the solvent is distilled off to obtain crude bis(tri-n-lower alkylstannyl)-5-halogenouracil.
  • reaction thus formed due to the susceptibility thereof to atmospheric moisture, is immediately subjected, without isolation or intermediate purification and with or without solvent substitution, to the succeeding reaction.
  • This reaction can be carried out in a solvent immiscible with water and having a suitable boiling point, as represented by aprotic solvents such as benzene or toluene. As this reaction is reversible reaction, it can be advanced to the right-hand side by eliminating water from the system.
  • the novel compound constituting the object of the present invention can be obtained quantitatively by refluxing the reaction mixture in an aprotic solvent such as benzene, carbon tetrachloride or toluene while eliminating water formed during the reaction.
  • an aprotic solvent such as benzene, carbon tetrachloride or toluene
  • the compounds thus obtained in this reaction can be easily hydrolized with water or ethanol into the original 2,5-disubstituted pyrimidine derivative.
  • the lower alkyl radical in the above reaction formula is not subjected to limitation as the alkylstannyl radical is cleaved by the following condensation reaction and does not contribute to the reaction. It is therefore possible to employ a bis(trilower alkylstannyl)oxide provided with a lower alkyl radical easily available and manipulatable.
  • the compounds are novel substances which can be utilized as important intermediates for the syntheses of various nucleosides for which excellent physiological activities are expected.
  • ⁇ -nucleosides having excellent physiological activities for example anticancer effect
  • said lower alkyl radical represented by Alk in the above-mentioned general formula can be mentioned methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and hexyl radicals, and the halogen atom represented by R can be exemplified by a fluorine, chlorine or bromine atom.
  • the lower alkyl radicals represented by R can be any of the above-mentioned lower alkyl radicals and can be same as or different.
  • the desired compound can be prepared by reacting bis(tri-lower alkylstannyl)-5-halogenouracil obtained as explained above with a 2-substituted tetrahydrofurane represented by the following general formula: ##STR4## wherein X is a halogen atom, a lower alkyloxy or aralkyloxy radical, a lower alkylcarbonyloxy radical or an arylcarbonyloxy radical.
  • Said halogen can for example be chlorine, bromine, fluorine or iodine;
  • said lower alkyloxy radical can be methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy or pentoxy;
  • said lower alkylcarbonyloxy radical can be acetoxy, propionyloxy, butanoyloxy, pentaoyloxy, or hexaoyloxy; and said arylcarbonyloxy radical can be benxoxy, paramethylbenzoxy or parabromobenzoxy and aralkyoxy radical can be benzyloxy or phenylethyloxy.
  • 2-sustituted tetrahydrofurane are 2-acetoxytetrahydrofurane, 2-chlorotetrahydrofurane, 2-methoxytetrahydrofurane, 2-benzoxytetrahydrofurane, 2-(p-nitrobenzoxy)tetrahydrofurane and 2-(p-tolylbenzoxy)tetrahydrofurane.
  • the above-mentioned reaction can be conducted within a temperature range of from about -50° C. to about 100° C. and for a period of about 30 minutes to about 20 hours, and is characterized by the fact that the reaction product varies dependent on the molar ratio of reactants, reaction temperature and reaction period.
  • said reaction provides N 1 -bis(2'-tetrahydrofuranyl)-5-halogenouracil (hereinafter called compound I), N 3 -bis(2'-tetrahydrofuranyl)-5-halogenouracil (hereinafter called compound II), N,N'-bis(2'-tetrahydrofuranyl)-5-halogenouracil (hereinafter called compound III) or a mixture of I and II, depending upon the reaction conditions.
  • compound I N 1 -bis(2'-tetrahydrofuranyl)-5-halogenouracil
  • compound II N 3 -bis(2'-tetrahydrofuranyl)-5-halogenouracil
  • compound III N,N'-bis(2'-tetrahydrofuranyl)-5-halogenouracil
  • Said reaction between bis(tri-lower alkylstannyl)-5-halogenouracil and said 2-substituted tetrahydrofurane is preferably conducted in a solution in a chlorinated hydrocarbon such as dichloromethane and if necessary in the presence of Friedel-Crafts catalyst.
  • a chlorinated hydrocarbon such as dichloromethane
  • Friedel-Crafts catalysts are stannic chloride, BF 3 etherate, AlCl 3 , PCl 3 and ZnCl 2 .
  • Such catalyst is not required in case the radical X in said 2-substituted tetrahydrofurane is a halogen atom, but otherwise the reaction can be made to proceed advantageously in the presence of a Lewis acid in a calculated or excessive amount.
  • solvents employable in said reaction are dichloroethane, tetrachlorethane, trichlorethane, chloroform, carbon tetrachloride, acetonitrile, nitromethane, ethyl acetate, benzene etc.
  • the amount of catalyst is variable according to the reactants. An amount of at least 1 molar amount is desirable in case said radical X is alkoxy, alkyloxycarbonyl or aryloxycarbonyl, but an amount of 0.1-0.2 molar amount is enough for the progress of reaction in case said radical X is a halogen atom. In general an elevated amount of catalyst provides a higher reaction speed but does not give direct effect on the yield of product.
  • the reaction temperature is dependent on the 2-substituted tetrahydrofurane to be employed in the reaction, and is lowered preferably to a range of -5° C.-40° C. in case of 2-halogenated tetrahydrofurans, particularly 2-chlorotetrahydrofurane, which are apt to decompose at ambient temperature.
  • the reaction temperature is subject to no specific limitation in case of other 2-substituted tetrahydrofurans, and can be suitably selected within a range from -10° C. to 100° C. according to the desired product.
  • the preferred reaction temperature is within a range from -5° C. to 30° C., more preferably within a range from -5° C. to 10° C.
  • This reaction provides principally 1-substituted compound (compound I) in case of a short reaction time since the nitrogen atom in 1-position is at first activated by substitution of uracil derivative with alkylstannyl radical. Successively there is formed, in case of a reaction time over 3 hours, 3-substituted compound (compound II) which is presumably generated by migration of substituent in 1-position to 3-position, and the ratio of 1-substituted compound and 3-substituted compound is approximately 1:1 and remains unchanged in an equilibrium state even when the reaction time is prolonged to 20 hours.
  • the reaction time is influenced by the reaction temperature
  • the mono-substituted uracil obtained is variable according to the reaction time and is principally the compound I in case the reaction time is short, while it is a mixture of the compounds I and II in case the reaction time is extended.
  • this reaction provides mono-substituted compounds in case the molar ratio of uracil derivative and tetrahydrofurane derivative is within the range of 1:1.0-1.5 preferably 1:1.0-1.2, a di-substituted compound in case said ratio is 1:2 or higher, or a mixture of mono- and di-substituted compounds at a molar ratio therebetween, although the species and ratio of reaction products are variable to a certain extent depending on various factors such as reaction time, reaction temperature and amount of catalyst.
  • the N 1 -monosubstituted compound (compound I) is obtainable in a reaction with a molar ratio within a range of 1:1.-1.5 preferably 1:1.0-1.2.
  • the reaction temperature and reaction time are not critical and variable in ranges respectively of -50° C. to 100° C. and of 30 minutes to 3 hours, preferably, however, within ranges of -5° to 10° C. and of 30 minutes to 2 hours.
  • the reaction temperature and reaction time are variable with ranges respectively of -50° C. to 100° C. and of 3 to 20 hours, preferably, however, within ranges of -5° to 10° C. and of 5 to 10 hours. In this case the reaction time is naturally shortened at a higher reaction temperature.
  • N 1 -mono-substituted compound (compound I) and N 3 -mono-substituted compound (compound II) can be respectively isolated from such mixture by means of a chromatographic method. Both compounds are endowed with pharmaceutical effects as explained before. Particularly N 3 -mono-substituted compound is considered capable of exhibiting an anticancer effect similar to that of N 1 -substituted compound.
  • N 1 ,N 3 -di-substituted compound (compound III) is obtainable in a reaction conducted at a molar ratio of bis(tri-lower alkyl stannyl)-5-fluorouracil to 2-substituted tetrahydrofurane equal to or higher than 1:2.
  • the preferred range of said molar ratio is from 1:2 to 1:3, as the use of an overly excessive amount of 2-substituted tetrahydrofurane does not improve the yield of desired compound but merely results in a loss of 2-substituted tetrahydrofurane.
  • a reaction conducted with a molar ratio lower than 1:2 will lead to the formation of a mixture of said di-substituted compound (compound III) and said N 1 -mono-substituted compound (compound I). With a further prolonged reaction time in this case there will be formed a mixture of N 1 ,N 3 -di-substituted compound, N 1 -mono-substituted compound and N 3 -mono-substituted compound due to the transformation of N 1 -monosubstituted compound (compound I) into N 3 -mono-substituted compound (compound II).
  • the reaction in this case can be advantageously conducted at a reaction temperature and a reaction period within ranges respectively of -50° to 100° C. and of 30 minutes to 3 hours, most preferably of -5° to 10° C. and of 30 minutes to 1 hour.
  • the reaction time is naturally shortened at a higher reaction temperature, and a prolonged reaction time, for example of 7 hours, will result in a lowered yield of the desired products.
  • the reaction according to the process of the present invention can be conducted in the following manner.
  • the uracil derivative and the tetrahydrofurane derivative are dissolved in a solvent, maintained at a determined temperature and reacted under agitation for a given period with the addition of a given amount of catalyst at one time or in divided portions.
  • reaction mixture is poured over an ice-alkali solution mixture to decompose the catalyst or to transfer it into the aqueous phase.
  • aqueous phase is extracted with a solvent, and the extract is washed with water, combined with organic phase, dried and concentrated to obtain the reaction product which is then recrystallized.
  • reaction mixture is added with an alcohol to decompose the catalyst.
  • alcohols such as methanol
  • the remaining residue is dissolved in a solvent such as chloroform, and the unreacted 5-halogenouracil undissolved therein is recovered by filtration.
  • the chloroform solution is concentrated and added with hexane to precipitate the reaction product which can be collected by filtration, eventually followed by recrystallization for further purification.
  • bis(tri-alkylstannyl)oxide can be recovered from the filtrate in the following manner.
  • Said filtrate is refluxed with alcoholic solution of alkali hydroxide, and the obtained reaction mixture, from which alcohol is eliminated by distillation is added with water to remove remaining alkali, and extracted with a polar solvent such as methylene chloride. The extract is evaporated dry to recover bis(tri-alkylstannyl)oxide.
  • N 1 -substituted compound or N 1 ,N 3 -di-substituted compound can be obtained in isolated state by means of the above-mentioned processes.
  • each component can be isolated from such mixtures by means of a chromatographic procress or a fractional crystallization.
  • the present inventors have found that the N 1 ,N 3 -di-substituted compound can be converted, through acidolysis thereof to selectively cleave the substituent on the nitrogen atom in 3-position, into N 1 -mono-substituted compound.
  • the N 1 ,N 3 -di-substituted compound resulting from the above-mentioned reaction is stirred for a short period with a Lewis acid or an inorganic acid, and the reaction mixture is poured in a mixture of ice and alkali solution to separate the organic phase.
  • the aqueous phase is extracted with an organic solvent, and the extract, united with the organic phase, is dried, then concentrated under a reduced pressure and subjected to a chromatographic separation to obtain the N 1 -mono-substituted compound with a high yield.
  • hydrolysis mentioned above can be advantageously conducted with hydrochloric acid, acetic acid or a Lewis acid of a concentration of 0.01 to 10% and with an agitation for 1 minute to 24 hours at room temperature.
  • Example 1 The process of Example 1 was repeated with 1.91 gr. (0.01 mol) of 5-bromouracil to obtain bis(tri-n-butylstannyl)-5-bromouracil.
  • Example 1 The process of Example 1 was repeated with 51.8 gr. (0.1 mol) of bis(tri-n-propylstannyl)oxide instead of bis(tri-n-butylstannyl)oxide to obtain bis(tri-n-propylstannyl)-5-fluorouracil.
  • Example 4 The process of Example 4 was repeated with bis(tri-n-butylstannyl)-5-bromouracil to obtain 0.177 gr. (yield 69%) of N 1 -tetrahydrofuranyl-5-bromouracil.
  • Example 4 The process of Example 4 was repeated with 6.24 gr. (0.01 mol) of bis(tri-n-propylstannyl)-5-fluorouracil instead of bis(tri-n-butylstannyl)-5-fluorouracil to obtain 1.54 gr. (yield 77.0%) of N 1 -(2'-tetrahydrofuranyl)-5-fluorouracil.
  • Example 4 The process of Example 4 was repeated with the reaction time extended to 7 hours to obtain 1-(tetrahydrofuranyl)-5-fluorouracil and N 3 -(2'-tetrahydrofuranyl)-5-fluorouracil in 1:1 molar ratio. Said reaction products were isolated respectively in amount of 0.06 gr. (yield 30%) and 0.05 gr. (yield 25%) through the procedure and chromatographic separation described in the Example 4.
  • the filtrate obtained after separation of 4.2 gr. of crystals in the Example 7 were concentrated, and refluxed for ca. 5 hrs. with 4 gr. of sodium hydroxide and 150 ml of methanol. After elimination of methanol by distillation, the reaction mixture was added with water and extracted with methylene chloride. The methylene chloride was distilled off to obtain an oily residue, from which a fraction distilling between 150° and 158° C. was collected to recover bis(tri-n-butylstannyl)oxide. The yield of recovery was 80%.
  • Example 4 The process of Example 4 was repeated with 0.2 ml of boron trifluoride etherate instead of stannic chloride to obtain 1.4 gr. of N 1 -(2'-tetrahydrofuranyl)-5-fluorouracil (yield 70%).
  • Example 4 The process of Example 4 was repeated with reaction time prolonged to 7 hours to obtain N 1 -(tetrahydrofuranyl)-5-fluorouracil and N 3 -(tetrahydrofuranyl)-5-fluorouracil in 1:1 molar ratio.
  • the products were treated as described in the Example 4, then dissolved in toluene-ethyl acetate (1:1) mixture and subjected to chromatographic separation, which eluded at first 0.060 gr. (yield 30%) of N 1 -substituted compound and then 0.050 gr. (yield 25%) of N 3 -substituted compound.
  • Example 15 The process of Example 15 was repeated with 0.13 gr. (1 mmol) of 2-acetoxytetrahydrofurane to obtain 0.058 gr. (yield 29%) of N 1 -(tetrahydrofuranyl)-5-fluorouracil and 0.052 gr. (yield 26.0%) of N 3 -(tetrahydrofuranyl)-5-fluorouracil.
  • Example 15 The process of Example 15 was repeated with 0.10 gr. (1 mmol) of 2-methoxytetrahydrofurane to obtain 0.060 gr. (yield 30.0%) of N 1 -(tetrahydrofuranyl)-5-fluorouracil and 0.052 gr. (yield 26.0%) of N 3 -(tetrahydrofuranyl)-5-fluorouracil.
  • Example 15 The process of Example 15 was repeated with 0.11 gr. (1 mmol) of 2-chlorotetrahydrofurane and without stannic chloride to obtain 0.064 gr. (yield 32.0%) of N 1 -(tetrahydrofuranyl)-5-fluorouracil and 0.048 gr. (yield 24.0%) of N 3 -(tetrahydrofuranyl)-5-fluorouracil.
  • Example 15 The process of Example 15 was repeated with 0.24 gr. (1 mmol) of 2-(p-nitrobenzoyl)tetrahydrofurane to obtain 0.05 gr. (yield 29.5%) of N 1 -(tetrahydrofuranyl)-5-fluorouracil and 0.052 gr. (yield 26.0%) of N 3 -(tetrahydrofuranyl)-5-fluorouracil.
  • Example 15 The process of Example 15 was repeated with 0.22 gr. (1 mmol) of 2-(p-tolylbenzoxy)-tetrahydrofurane to obtain 0.058 gr. (yield 29.0%) of N 1 -(tetrahydrofuranyl)-5-fluorouracil and 0.050 gr. (yield 25.0%) of N 3 -(tetrahydrofuranyl)-5-fluorouracil.
  • Example 18 The process of Example 18 was repeated with 0.09 gr. (1 mmol) of 2-chlorotetrahydrofurane to obtain 0.062 gr. (yield 31.0%) of N 1 -(tetrahydrofuranyl)-5-fluorouracil and 0.051 gr. (yield 25.5%) of N 3 -(tetrahydrofuranyl)-5-fluorouracil.
  • Example 15 The process of Example 15 was repeated but with a reaction time of 4 hours and with a reaction temperature of 20° C. to obtain 0.066 gr. (yield 33%) of N 1 -(tetrahydrofuranyl)-5-fluorouracil and 0.046 gr. (yield 23%) of N 3 -(tetrahydrofuranyl)-5-fluorouracil.
  • Example 16 The process of Example 16 was repeated but with a reaction time of 4 hours and a reaction temperature of 20° C. to obtain 0.064 gr. (yield 32%) of N 1 -(tetrahydrofuranyl)-5-fluorouracil and 0.046 gr. (yield 23%) of N 3 -(tetrahydrofuranyl)-5-fluorouracil.
  • Example 18 The process of Example 18 was repeated but with a reaction time prolonged to 7 hours to obtain 0.077 gr. (yield 30%) of N 1 -(tetrahydrofuranyl)-5-bromouracil and 0.062 gr. (yield 24%) of N 3 -(tetrahydrofuranyl)-5-bromouracil.
  • Example 24 The process of Example 24 was repeated but with 0.13 gr. (1 mmol) of 2-acetoxytetrahydrofurane to obtain 0.075 gr. (yield 29%) of N 1 -(tetrahydrofuranyl)-5-bromouracil and 0.064 gr. (yield 25%) of N 3 -(tetrahydrofuranyl)-5-bromouracil.
  • Example 26 The process of Example 26 was repeated but with 6.5 gr. (0.05 mol) of 2-acetoxytetrahydrofurane to obtain 6.0 gr. (yield 88.0%) of N,N'-bis-(2'-tetrahydrofuranyl)-5-fluorouracil.
  • Example 26 The process of Example 26 was repeated but with 5.3 gr. (0.05 mol) of 2-methoxytetrahydrofurane to obtain 6.0 gr. (yield 88.0%) of N,N'-bis(2'-tetrahydrofuranyl)-5-fluorouracil.
  • Example 26 The process of Example 26 was repeated but with 9.6 gr. (0.05 mol) of 2-benzoxytetrahydrofurane and 14.2 gr. (0.02 mol) of bis(tri-n-butylstannyl)-5-fluorouracil to obtain 5.1 gr. (yield 95.0%) of N,N'-bis(2'-tetrahydrofuranyl)-5-fluorouracil.
  • Example 26 The process of Example 26 was repeated but with 10.5 gr. (0.06 mol) of 2-benzoxytetrahydrofurane and 14.2 gr. (0.02 mol) of bis(tri-n-butylstannyl)-5-fluorouracil to obtain 5.0 gr. (yield 93.5%) of N,N'-bis-(2'-tetrahydrofuranyl)-5-fluorouracil.
  • Example 26 The process of Example 26 was repeated but with a reaction time of 3 hours to obtain 5.6 gr. (yield 83.0%) of N,N'-bis-(2'-tetrahydrofuranyl)-5-fluorouracil.
  • Example 26 The process of Example 26 was repeated but with a reaction time of 7 hours to obtain 5.1 gr. (yield 75.0%) of N,N'-bis(2'-tetrahydrofuranyl)-5-fluorouracil.
  • Example 26 The process of Example 26 was repeated but with 15.8 gr. (0.025 mol) of bis(tri-n-propylstannyl)-5-fluorouracil to obtain 6.1 gr. (yield 90.3%) of N,N'-bis-(2'-tetrahydrofuranyl)-5-fluorouracil.
  • Example 26 The process of Example 26 was repeated but with 10.5 gr. (0.06 mol) of 2-benzoxytetrahydrofurane and 23.5 gr. (0.04 mol) of bis(tri-n-butylstannyl)-5-fluorouracil to obtain 5.1 gr. (yield 47.0%) of N,N'-bis-(2'-tetrahydrofuranyl)-5-fluorouracil and 1.2 gr. (yield 14.5%) of N 1 -(2'-tetrahydrofuranyl)-5-fluorouracil.
  • Example 39 The process of Example 39 was repeated but with 5.3 gr. (0.05 mol) of 2-methoxytetrahydrofurane to obtain 4.4 gr. (yield 88.0%) of N 1 -(2'-tetrahydrofuranyl)-5-fluorouracil.
  • Example 39 The process of Example 39 was repeated but with 9.6 gr. (0.05 mol) of 2-benzoxytetrahydrofurane and 14.2 gr. (0.02 mol) of bis(tri-n-butylstannyl)-5-fluorouracil to obtain 3.8 gr. (yield 95.0%) of N 1 -(2'-tetrahydrofuranyl)-5-fluorouracil.
  • Example 39 The process of Example 39 was repeated but with 10.5 gr. (0.06 mol) of 2-benzoxytetrahydrofurane and 14.2 gr. (0.02 mol) of bis(tri-n-butylstannyl)-5-fluorouracil to obtain 3.7 gr. (yield 92.5%) of N 1 -(2'-tetrahydrofuranyl)-5-fluorouracil.
  • Example 38 The process of Example 38 was repeated but with a reaction time of 3 hours to obtain 4.2 gr. (yield 83.0%) of N 1 -(2'-tetrahydrofuranyl)-5-fluorouracil.
  • Example 38 The process of Example 38 was repeated but with a reaction time of 7 hours to obtain 3.8 gr. (yield 76.0%) of N 1 -(2'-tetrahydrofuranyl)-5-fluorouracil.
  • Example 38 The process of Example 38 was repeated but with 15.8 gr. (0.025 mol) of bis(tri-n-propylstannyl)-5-fluorouracil obtained in Example 3 to obtain 4.5 gr. (yield 90.0%) of N 1 -(2'-tetrahydrofuranyl)-5-fluorouracil.
  • Example 1 The process of Example 1 was repeated with 12.7 gr. (0.1 mol) of 2-hydroxy-5-methyl-5-hydroxypyrimidine to obtain 2,4-bis(tri-n-butylstannyl)-5-methylpyrimidine in an approximately quantitative yield.
  • Example 47 The process of Example 47 was repeated with 19.1 gr. (0.1 mol) of 2-hydroxy-5-bromo-4-hydroxypyrimidine to obtain 2,4-bis(tri-n-butylstannyl)-5-bromopyrimidine in an approximately quantitative yield.
  • Example 47 The process of Example 47 was repeated with 12.8 gr. (0.1 mol) of 2-thio-4-hydroxyprimidine to obtain 2-thio(tri-n-butylstannyl)-4-tri-n-butylstannylpyrimidine in an approximately quantitative yield.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to a novel process for producing pyrimidine nucleosides by a reaction between bis(tri-lower alkylstannyl)-5-halogenouracil and 2-substituted tetrahydrofurane. The novel process of the present invention makes it possible to obtain, depending upon the manner of substitution of tetrahydrofurane residue on two nitrogen atoms N1 and N3 of 5-halogenouracil, N1-mono-substituted compound, N3-mono-substituted compound and N1,N-di-substituted compound among which the last can be converted by hydrolysis thereof into N1-mono-substituted compound. The present invention further relates to novel N3-mono-substituted compounds and N1,N3-di-substituted compounds obtained by such process. The present invention still further relates to novel bis-(tri-lower alkylstannyl)-5-halogenouracil used in the present invention as a raw compound.

Description

FIELD OF THE INVENTION
The present invention relates to novel pyrimidine nucleosides or 5-halogenouracil substituted on the nitrogen atoms thereof with a 2'-tetrahydrofuranyl radical and a process for producing the same.
In recent years pyrimidine nucleosides have drawn attention as pharmaceuticals having diversified pharmaceutical effects, for example as an anticancer medicine with excellent therapeutic effect on various types of cancers.
Also pyrimidine nucleosides have become known as an antimetabolic agent in the fields of pharmaceuticals and agricultural chemicals and as a condiment in the food industries.
Among the above-mentioned anticancer medicines most salient is 1-(tetrahydro-2-furanyl)-5-fluorouracil which is commonly known under the name of Ftorafur.
Ftorafur is a derivative of 5-fluorouracil (5-FU) which is bonded, at the N-1 position thereof, with 2-position of tetrahydrofurane residue, and functions as a masked compound which is gradually converted into an active compound such as 5-FU in the blood vessels and internal organs.
In clinical studies with injective administration Ftorafur proved to be similarly effective as 5-FU against cancers of the stomach, colon, rectum and other parts of the digestive tract, lung cancer and particularly gland cancers. The total dose required for positive result is 20-40 grams in total with a daily dose of 800-1,200 mgs.
Ftorafur in general shows significantly lighter secondary effects than in 5-FU, and causes almost no diarrhoea, perforation, medullary disorders or other serious secondary troubles which frequently occur in the administration of 5-FU. From this standpoint Ftorafur proved to be clinically far superior to 5-FU.
Also in oral administration, the antitumor effect of Ftorafur is particularly marked in breast cancer, and is comparable, in case of cancers of the digestive tract such as stomach cancer, to the effect of 5-FU obtained by intravenous administration. Also in this case, Ftorafur is far superior to 5-FU with respect to the secondary effects.
DESCRIPTION OF THE PRIOR ART
Pyrimidine nucleosides are already known to be synthesizable by means of so-called silicon process or mercury process, most prior reference being devoted to the former process.
In said silicon process, pyrimidine nucleosides are obtained by reacting bistrimethylsilyl derivative of uracil with acylated sugars or furane derivatives in the presence of Friedel-Crafts catalyst.
For example U. Nieaballa and Helmut Vorgriggen (Angewandte Chemie 82, No. 11, 449-450) reported the synthesis of N1 -nucleoside of uracil by reacting bis-trimethylsilyl derivative of uracil with 1-O-acetyl-2,3,5-tri-O-benzoyl-D-riboflanose in the presence of a Friedel-Crafts catalyst.
Also the Japanese Patent Publication No. 8551/1965 published on May 4, 1965 discloses a process for producing pyrimidine nucleosides represented by a general formula: ##STR1## wherein R3 and R4 are members selected from hydrogen atom, hydroxyl radical, amino radical, mercapto radical and methyl radical and Y is a glucosyl radical; which comprises reacting a pyrimidine derivative represented by a general formula: ##STR2## wherein R3 and R4 have the same meaning as explained above, with a tri-(lower alkyl)-chlorosilane or hexa(lower alkyl)-disilazane in the presence of a tertinary amine and reacting thus obtained reaction product with a halogeno-pentose or a halogeno-hexose.
Furthermore the British Pat. No. 1,168,391 published Oct. 22, 1969 discloses a process for producing N1 -(2'-furanizyl)uracil or N1 -(2'-pyranizyl)uracil by reacting a bistrimethylsilyl derivative of uracil with 2-chlorofuranizine or 2-chlorophyranizine.
Said mercury process consists of a reaction between monomethylated pyrimidine and a 2-substituted tetrahydrofurane at a low temperature as reported in Doklady Akademii Nauk SSSR 176, No. 2, 332-335(1967) of which English translation was published in DOKLADY CHEMISTRY 176, No. 1-3, 798-801 Sept. (1967).
The synthesis of Ftorafur which is N1 -(2'-tetrahydrofuranyl)-5-fluorouracil, and the related compounds thereof by said silicon process or mercury process is already known in the various patents and patent applications which are enumerated here: Giller, U.S. Pat. No. 3,635,946; Giller U.S. Pat. No. 3,912,734; La Roche, U.S. Pat. No. 2,802,005; La Roche, U.S. Pat. No. 3,354,160; Knuniants, U.S. Pat. No. 3,682,917; Giller, U.S. Pat. No. 3,846,429; Taiho, Japanese Patent Publication No. 64281/1975; Taiho, Japanese Patent Publication No. 50383/1975; Taiho, Japanese Patent Publication No. 50384/1975; Taiho, Japanese Patent Publication No. 105673/1975; Taiho, Japanese Patent Publication No. 105,674/1975; Asahi, Japanese Patent Publication No. 127,981/1974; Asahi, Japanese Patent Publication No. 127,982/1974; and Asahi, Japanese Patent Publication No. 127,983/1974.
SUMMARY OF THE INVENTION
As explained in the foregoing, the pyrimidine nucleosides, particularly N1 -(2'-tetrahydrofuryl)-5-fluorouracil known under a name of FT-207 "Fotrafur" and the related compounds thereof, are known to be synthesizable either by said silicon process or by mercury process. However, said mercury process is disadvantageous in the use of a low-temperature reaction to be effected as low as -40° C. and also in the use of toxic mercury salts.
On the other hand said silicon process, though investigated by various investigators as mentioned before, is still associated with drawbacks, namely, that the side product resulting from trialkylsilicon is not recoverable and that pyrimidine trimethylsilylated in the course of reaction are difficult to handle due to the low stability thereof in the air. An another drawback in this process is that the trimethylsilylation is more difficult to realize in comparison with trialkylstannylation.
The present invention is based on a tin process utilizing a reaction between a stannylated pyrimidine derivative and a tetrahydrofurane derivative which, avoiding the above-mentioned drawbacks, makes it possible to obtain the desired compound with an elevated yield and at a nearly ambient temperature, and further makes it possible to obtain novel compounds which have not been reported in the prior references.
The object of the present invention, therefore, is to provide a process for producing pyrimidine nucleosides by means of such tin process.
An another object of the present invention is to provide a novel process for producing pyrimidine nucleosides wherein 5-halogenouracil is substituted, on a carbon atom thereof, with a tetrahydrofurane residue, by means of said tin process.
Still another object of the present invention is to provide a process for producing N1 -(2'-tetrahydrofuryl)-5-fluorouracil by means of said tin process.
Still another object of the present invention is to provide novel pyrimidine nucleosides obtained in connection with the development of said tin process.
Still further object of the present invention is to provide novel bis(tri-lower alkylstannyl)-5-halogenouracil.
Still another object of this invention is to provide a process for producing the said stannyl uracil derivatives.
Still other objects of the present invention will be clear from the following description of the present invention.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
The present invention is to provide a process for producing pyrimidine nucleosides wherein a tetrahydrofurane reside is bonded to nitrogen atoms of pyrimidine nucleus by reacting a bis(tri-n-lower alkylstannyl)-5-halogenouracil with a 2-substituted tetrahydrofurane, also to provide pyrimidine nucleosides obtained by such process.
The bis(tri-n-lower alkylstannyl)-5-halogenouracil which is utilized as a starting material is a novel substance obtained by a reaction between 5-halogenouracil and bis(tri-n-lower alkylstannyl)oxide in a manner as explained in the following.
5-halogenouracil is heated under reflux with equimolar or approximately equimolar amount of bis(trilower alkylstannyl)oxide in the presence of an aprotic solvent such as toluene with continuous elimination of water. After the distillation of water is terminated, the solvent is distilled off to obtain crude bis(tri-n-lower alkylstannyl)-5-halogenouracil.
The reaction thus formed, due to the susceptibility thereof to atmospheric moisture, is immediately subjected, without isolation or intermediate purification and with or without solvent substitution, to the succeeding reaction.
The foregoing reaction can be represented by the following reaction formula: ##STR3## wherein Hal represents fluorine, chlorine or bromine, Alk represents a lower alkyl radical and Y represents oxygen or sulfur atom. This reaction can be carried out in a solvent immiscible with water and having a suitable boiling point, as represented by aprotic solvents such as benzene or toluene. As this reaction is reversible reaction, it can be advanced to the right-hand side by eliminating water from the system.
Thus, in the above-mentioned reaction of 2,5-disubstituted pyrimidine derivative with bis(tri-lower alkylstannyl)oxide, the novel compound constituting the object of the present invention can be obtained quantitatively by refluxing the reaction mixture in an aprotic solvent such as benzene, carbon tetrachloride or toluene while eliminating water formed during the reaction.
The compounds thus obtained in this reaction can be easily hydrolized with water or ethanol into the original 2,5-disubstituted pyrimidine derivative.
The lower alkyl radical in the above reaction formula is not subjected to limitation as the alkylstannyl radical is cleaved by the following condensation reaction and does not contribute to the reaction. It is therefore possible to employ a bis(trilower alkylstannyl)oxide provided with a lower alkyl radical easily available and manipulatable.
The compounds are novel substances which can be utilized as important intermediates for the syntheses of various nucleosides for which excellent physiological activities are expected. For example β-nucleosides having excellent physiological activities (for example anticancer effect) can be obtained by reacting the object compounds of the present invention with completely acylated sugars.
As examples of said lower alkyl radical represented by Alk in the above-mentioned general formula can be mentioned methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl and hexyl radicals, and the halogen atom represented by R can be exemplified by a fluorine, chlorine or bromine atom. Also the lower alkyl radicals represented by R can be any of the above-mentioned lower alkyl radicals and can be same as or different.
The followings are examples of the compound of the general formula (I): 2,4-bis(tri-n-butylstannyl)-5-fluorouracil; 2,4-bis(tri-n-butylstannyl)uracil; 2,4-bis(tri-isobutylstannyl)-5-methyluracil, 2,4-bis(tri-n-propylstannyl)-5-bromouracil; 2-thio(tri-n-butylstannyl)-4-tri-n-butylstannyluracil; 2,4-bis(triethylstannyl)-5-bromouracil; 2-thio(tri-n-pentylstannyl)-4-(tri-n-propylstannyl)uracil; 2,4-bis(trimethylstannyl)-5-butyluracil; and 2,4-bis(triethylstannyl)uracil.
According to the present invention the desired compound can be prepared by reacting bis(tri-lower alkylstannyl)-5-halogenouracil obtained as explained above with a 2-substituted tetrahydrofurane represented by the following general formula: ##STR4## wherein X is a halogen atom, a lower alkyloxy or aralkyloxy radical, a lower alkylcarbonyloxy radical or an arylcarbonyloxy radical. Said halogen can for example be chlorine, bromine, fluorine or iodine; said lower alkyloxy radical can be methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy or pentoxy; said lower alkylcarbonyloxy radical can be acetoxy, propionyloxy, butanoyloxy, pentaoyloxy, or hexaoyloxy; and said arylcarbonyloxy radical can be benxoxy, paramethylbenzoxy or parabromobenzoxy and aralkyoxy radical can be benzyloxy or phenylethyloxy.
The preferred examples of said 2-sustituted tetrahydrofurane are 2-acetoxytetrahydrofurane, 2-chlorotetrahydrofurane, 2-methoxytetrahydrofurane, 2-benzoxytetrahydrofurane, 2-(p-nitrobenzoxy)tetrahydrofurane and 2-(p-tolylbenzoxy)tetrahydrofurane.
The above-mentioned reaction can be conducted within a temperature range of from about -50° C. to about 100° C. and for a period of about 30 minutes to about 20 hours, and is characterized by the fact that the reaction product varies dependent on the molar ratio of reactants, reaction temperature and reaction period.
More specifically, said reaction provides N1 -bis(2'-tetrahydrofuranyl)-5-halogenouracil (hereinafter called compound I), N3 -bis(2'-tetrahydrofuranyl)-5-halogenouracil (hereinafter called compound II), N,N'-bis(2'-tetrahydrofuranyl)-5-halogenouracil (hereinafter called compound III) or a mixture of I and II, depending upon the reaction conditions. Said compounds are shown in the following: ##STR5##
Said reaction between bis(tri-lower alkylstannyl)-5-halogenouracil and said 2-substituted tetrahydrofurane is preferably conducted in a solution in a chlorinated hydrocarbon such as dichloromethane and if necessary in the presence of Friedel-Crafts catalyst. Preferred examples of such Friedel-Crafts catalysts are stannic chloride, BF3 etherate, AlCl3, PCl3 and ZnCl2. Such catalyst is not required in case the radical X in said 2-substituted tetrahydrofurane is a halogen atom, but otherwise the reaction can be made to proceed advantageously in the presence of a Lewis acid in a calculated or excessive amount.
Other examples of solvents employable in said reaction are dichloroethane, tetrachlorethane, trichlorethane, chloroform, carbon tetrachloride, acetonitrile, nitromethane, ethyl acetate, benzene etc.
The amount of catalyst is variable according to the reactants. An amount of at least 1 molar amount is desirable in case said radical X is alkoxy, alkyloxycarbonyl or aryloxycarbonyl, but an amount of 0.1-0.2 molar amount is enough for the progress of reaction in case said radical X is a halogen atom. In general an elevated amount of catalyst provides a higher reaction speed but does not give direct effect on the yield of product.
The reaction temperature is dependent on the 2-substituted tetrahydrofurane to be employed in the reaction, and is lowered preferably to a range of -5° C.-40° C. in case of 2-halogenated tetrahydrofurans, particularly 2-chlorotetrahydrofurane, which are apt to decompose at ambient temperature.
The reaction temperature is subject to no specific limitation in case of other 2-substituted tetrahydrofurans, and can be suitably selected within a range from -10° C. to 100° C. according to the desired product. However the preferred reaction temperature is within a range from -5° C. to 30° C., more preferably within a range from -5° C. to 10° C.
This reaction provides principally 1-substituted compound (compound I) in case of a short reaction time since the nitrogen atom in 1-position is at first activated by substitution of uracil derivative with alkylstannyl radical. Successively there is formed, in case of a reaction time over 3 hours, 3-substituted compound (compound II) which is presumably generated by migration of substituent in 1-position to 3-position, and the ratio of 1-substituted compound and 3-substituted compound is approximately 1:1 and remains unchanged in an equilibrium state even when the reaction time is prolonged to 20 hours.
Although the reaction time is influenced by the reaction temperature, the mono-substituted uracil obtained is variable according to the reaction time and is principally the compound I in case the reaction time is short, while it is a mixture of the compounds I and II in case the reaction time is extended.
Generally speaking this reaction provides mono-substituted compounds in case the molar ratio of uracil derivative and tetrahydrofurane derivative is within the range of 1:1.0-1.5 preferably 1:1.0-1.2, a di-substituted compound in case said ratio is 1:2 or higher, or a mixture of mono- and di-substituted compounds at a molar ratio therebetween, although the species and ratio of reaction products are variable to a certain extent depending on various factors such as reaction time, reaction temperature and amount of catalyst.
In the following there are shown preferred reaction conditions for each type of reaction product.
The N1 -monosubstituted compound (compound I) is obtainable in a reaction with a molar ratio within a range of 1:1.-1.5 preferably 1:1.0-1.2. In this case the reaction temperature and reaction time are not critical and variable in ranges respectively of -50° C. to 100° C. and of 30 minutes to 3 hours, preferably, however, within ranges of -5° to 10° C. and of 30 minutes to 2 hours.
For obtaining a mixture of N1 -mono-substituted compound (compound I) and N3 -mono-substituted compound (compound II), the reaction temperature and reaction time are variable with ranges respectively of -50° C. to 100° C. and of 3 to 20 hours, preferably, however, within ranges of -5° to 10° C. and of 5 to 10 hours. In this case the reaction time is naturally shortened at a higher reaction temperature.
The N1 -mono-substituted compound (compound I) and N3 -mono-substituted compound (compound II) can be respectively isolated from such mixture by means of a chromatographic method. Both compounds are endowed with pharmaceutical effects as explained before. Particularly N3 -mono-substituted compound is considered capable of exhibiting an anticancer effect similar to that of N1 -substituted compound.
Furthermore, the N1,N3 -di-substituted compound (compound III) is obtainable in a reaction conducted at a molar ratio of bis(tri-lower alkyl stannyl)-5-fluorouracil to 2-substituted tetrahydrofurane equal to or higher than 1:2. The preferred range of said molar ratio is from 1:2 to 1:3, as the use of an overly excessive amount of 2-substituted tetrahydrofurane does not improve the yield of desired compound but merely results in a loss of 2-substituted tetrahydrofurane.
A reaction conducted with a molar ratio lower than 1:2 will lead to the formation of a mixture of said di-substituted compound (compound III) and said N1 -mono-substituted compound (compound I). With a further prolonged reaction time in this case there will be formed a mixture of N1,N3 -di-substituted compound, N1 -mono-substituted compound and N3 -mono-substituted compound due to the transformation of N1 -monosubstituted compound (compound I) into N3 -mono-substituted compound (compound II).
The reaction in this case can be advantageously conducted at a reaction temperature and a reaction period within ranges respectively of -50° to 100° C. and of 30 minutes to 3 hours, most preferably of -5° to 10° C. and of 30 minutes to 1 hour. The reaction time is naturally shortened at a higher reaction temperature, and a prolonged reaction time, for example of 7 hours, will result in a lowered yield of the desired products.
The reaction according to the process of the present invention can be conducted in the following manner.
Preferably the uracil derivative and the tetrahydrofurane derivative are dissolved in a solvent, maintained at a determined temperature and reacted under agitation for a given period with the addition of a given amount of catalyst at one time or in divided portions.
After the completion of the reaction, the reaction mixture is poured over an ice-alkali solution mixture to decompose the catalyst or to transfer it into the aqueous phase. The aqueous phase is extracted with a solvent, and the extract is washed with water, combined with organic phase, dried and concentrated to obtain the reaction product which is then recrystallized.
In case of a reaction with a catalyst, such as boron trifluoride, decomposible with alcohols such as methanol, the reaction mixture is added with an alcohol to decompose the catalyst. After the elimination of solvent by distillation, the remaining residue is dissolved in a solvent such as chloroform, and the unreacted 5-halogenouracil undissolved therein is recovered by filtration. The chloroform solution is concentrated and added with hexane to precipitate the reaction product which can be collected by filtration, eventually followed by recrystallization for further purification. Also bis(tri-alkylstannyl)oxide can be recovered from the filtrate in the following manner.
Said filtrate is refluxed with alcoholic solution of alkali hydroxide, and the obtained reaction mixture, from which alcohol is eliminated by distillation is added with water to remove remaining alkali, and extracted with a polar solvent such as methylene chloride. The extract is evaporated dry to recover bis(tri-alkylstannyl)oxide.
The N1 -substituted compound or N1,N3 -di-substituted compound can be obtained in isolated state by means of the above-mentioned processes.
In case the reaction provides a mixture of N1 -substituted compound and N3 -substituted compound or a mixture of di-substituted compound and mono-substituted compounds, each component can be isolated from such mixtures by means of a chromatographic procress or a fractional crystallization.
Furthermore the present inventors have found that the N1,N3 -di-substituted compound can be converted, through acidolysis thereof to selectively cleave the substituent on the nitrogen atom in 3-position, into N1 -mono-substituted compound. For this purpose the N1,N3 -di-substituted compound resulting from the above-mentioned reaction is stirred for a short period with a Lewis acid or an inorganic acid, and the reaction mixture is poured in a mixture of ice and alkali solution to separate the organic phase. The aqueous phase is extracted with an organic solvent, and the extract, united with the organic phase, is dried, then concentrated under a reduced pressure and subjected to a chromatographic separation to obtain the N1 -mono-substituted compound with a high yield.
The hydrolysis mentioned above can be advantageously conducted with hydrochloric acid, acetic acid or a Lewis acid of a concentration of 0.01 to 10% and with an agitation for 1 minute to 24 hours at room temperature.
The present invention will be further clarified by the following examples, which are solely shown for the purpose of illustration and by no means limit the scope of the present invention.
EXAMPLE 1
1.30 gr. (0.01 mol) of 5-fluorouracil and 5.96 gr. (0.01 mol) of bis(tri-n-butylstannyl)oxide were heated under reflux in 100 ml of toluene, while water formed was continuously distilled off during the heating. After heating for ca. 20 hrs., toluene was removed by distillation to obtain bis(tri-n-butylstannyl)-5-fluorouracil.
Physical property
Nuclear magnetic resonance spectrum ('H, N.M.R.): (CDCl3): δH6, 7.10 (d,j=5 Hz).
EXAMPLE 2
The process of Example 1 was repeated with 1.91 gr. (0.01 mol) of 5-bromouracil to obtain bis(tri-n-butylstannyl)-5-bromouracil.
EXAMPLE 3
The process of Example 1 was repeated with 51.8 gr. (0.1 mol) of bis(tri-n-propylstannyl)oxide instead of bis(tri-n-butylstannyl)oxide to obtain bis(tri-n-propylstannyl)-5-fluorouracil.
EXAMPLE 4
0.192 gr. (1 mmol) of 2-benzoxytetrahydrofrane and 0.708 gr. (1 mmol) of bis(tri-n-butylstannyl)-5-fluorouracil obtained in the Example 1 were dissolved in 10 ml of dichloromethane, cooled at -5°-0° C., added with 0.26 gr. (1 mmol) of stannic chloride under agitation and maintained at 0°-5° C. After 30 to 60 minutes the reaction mixture was poured over a mixture of ice and sodium bicarbonate solution, and extracted with dichloromethane. The extract was washed with water, then dried over anhydrous magnesium sulfate, concentrated under a reduced pressure and passed through a silica gel column. The resulting product was recrystallized from ethanol to obtain 0.140 gr. (yield 70%) of N1 -(2'-tetrahydrofuranyl)-5-fluorouracil.
______________________________________                                    
Physical properties                                                       
______________________________________                                    
Melting point    165-167° C.                                       
N.M.R. spectrum  δ 6.0 ppm, 1H                                      
                 broad doublet J = 6 Hz                                   
______________________________________
EXAMPLE 5
The process of Example 4 was repeated with bis(tri-n-butylstannyl)-5-bromouracil to obtain 0.177 gr. (yield 69%) of N1 -tetrahydrofuranyl-5-bromouracil.
EXAMPLE 6
The process of Example 4 was repeated with 6.24 gr. (0.01 mol) of bis(tri-n-propylstannyl)-5-fluorouracil instead of bis(tri-n-butylstannyl)-5-fluorouracil to obtain 1.54 gr. (yield 77.0%) of N1 -(2'-tetrahydrofuranyl)-5-fluorouracil.
EXAMPLE 7
17.7 gr. (0.025 mol) of bis(tri-n-butylstannyl)-5-fluorouracil obtained in the Example 1 and 7.2 gr. (0.0375 mol) of 2-benzoyloxytetrahydrofurane were dissolved in 100 ml of dichloroethane. 2.48 gr. (0.0175 mol) of boron trifluoride etherate dissolved in 30 ml of dichloroethane was added dropwise from a dropping funnel over a period of 30 minutes to the above-obtained solution maintained at 15° C., and the resulting mixture was allowed to stand for 30 minutes to complete the reaction. After the completion of reaction, 30 ml of methanol was added and the solvent was eliminated by distillation. The resulting residue was dissolved in chloroform to recover undissolved 5-fluorouracil, and the chloroform solution was again concentrated and added with hexane. The resulting crystals were separated by filtration to obtain 4.2 gr. of N1 -(2'-tetrahydrofuranyl)-5-fluorouracil (yield 95%: m.p. 165°-167° C.). Also 0.35 gr. of 5-fluorouracil was recovered in the process.
EXAMPLE 8
The process of Example 4 was repeated with the reaction time extended to 7 hours to obtain 1-(tetrahydrofuranyl)-5-fluorouracil and N3 -(2'-tetrahydrofuranyl)-5-fluorouracil in 1:1 molar ratio. Said reaction products were isolated respectively in amount of 0.06 gr. (yield 30%) and 0.05 gr. (yield 25%) through the procedure and chromatographic separation described in the Example 4.
______________________________________                                    
Physical properties of N3-(2'-tetrahydrofuranyl)-                         
5-fluorouracil                                                            
______________________________________                                    
Melting point          125-127° C.                                 
N.M.R. spectrum        δ 5.85                                       
                       1H doublet                                         
______________________________________
EXAMPLE 9
The filtrate obtained after separation of 4.2 gr. of crystals in the Example 7 were concentrated, and refluxed for ca. 5 hrs. with 4 gr. of sodium hydroxide and 150 ml of methanol. After elimination of methanol by distillation, the reaction mixture was added with water and extracted with methylene chloride. The methylene chloride was distilled off to obtain an oily residue, from which a fraction distilling between 150° and 158° C. was collected to recover bis(tri-n-butylstannyl)oxide. The yield of recovery was 80%.
EXAMPLE 10
1.30 gr. (0.01 mol) of 2-acetoxytetrahydrofurane and 7.08 gr. (0.01 mol) of bis(tri-n-butylstannyl)-5-fluorouracil obtained in the Example 4 were dissolved in 100 ml of dichloromethane, cooled to -5° C. and added with 2.6 gr. (0.01 mol) of stannic chloride under agitation. After the completion of reaction (ca. 3 hrs.), the reaction mixture was poured over a mixture of ice and sodium bicarbonate solution, and extracted with dichloromethane. The extract was washed with water, then dried over anhydrous magnesium sulfate and concentrated under a reduced pressure. After passing a silica gel column, the obtained product was recrystallized from ethanol to obtain 1.5 gr. of N1 -(2'-tetrahydrofuranyl)-5-fluorouracil (yield 75%: m.p. 165°-167° C.).
EXAMPLE 11
1.06 gr. (0.01 mol) of 2-chlorotetrahydrofurane and 7.08 gr. (0.01 mol) of bis(tri-n-butylstannyl)-5-fluorouracil were dissolved in 100 ml. of dichloromethane and agitated at -5° C. for ca. 3 hrs. After the completion of reaction, the reaction mixture was poured over a mixture of ice and sodium bicarbonate solution, and extracted with dichloromethane. The extract was washed with water, dried over anhydrous magnesium sulfate and evaporated dry under a reduced pressure. After passing a silica gel column, the obtained product was recrystallized from ethanol to obtain 1.66 gr. of N1 -(2'-tetrahydrofuranyl)-5-fouorouracil (yield 83%: m.p. 165°-167° C. ).
EXAMPLE 12
1.02 gr. (0.01 mol) of 2-methoxytetrahydrofurane and 7.08 gr. (0.01 mol) of bis(tri-n-butylstannyl)-5-fluorouracil were dissolved in 100 ml of dichloromethane, and added at 10° C. and under agitation, with 2.6 gr. (0.01 mol) of stannic chloride. After completion of reaction for ca. 2 hrs., the reaction mixture was poured over a mixture of ice and sodium bicarbonate solution, and extracted with dichloromethane. The extract was washed with water, then dried over anhydrous magnesium sulfate and concentrated under a reduced pressure. After passing a silica gel column and concentration under a reduced pressure, the reaction product was recrystallized from ethanol to obtain 1.6 gr. of N1 -(2'-tetrahydrofuranyl)-5-fluorouracil (yield 80.0%: m.p. 165°-167° C.).
EXAMPLE 13
0.114 gr. (1 mmol) of 2-ethoxytetrahydrofurane and 0.708 gr. (1 mmol) of bis(tri-n-butylstannyl)-5-fluorouracil obtained in the Example 1 were dissolved in 10 ml of dichloromethane, cooled to -5° to 0° C., then added under agitation with 2.6 gr. (1 mmol) of stannic chloride and maintained at 0°-5° C. After reaction for 30 to 60 minutes, the reaction mixture was poured over a mixture of ice and sodium bicarbonate solution and extracted with dichloromethane. The extract was washed with water, dried over anhydrous magnesium sulfate and concentrated under a reduced pressure. After passing a silica gel column, the obtained product was recrystallized from ethanol to obtain 1.40 gr. of 1-(tetrahydrofuranyl)-5-fluorouracil (yield 70%).
EXAMPLE 14
The process of Example 4 was repeated with 0.2 ml of boron trifluoride etherate instead of stannic chloride to obtain 1.4 gr. of N1 -(2'-tetrahydrofuranyl)-5-fluorouracil (yield 70%).
EXAMPLE 15
The process of Example 4 was repeated with reaction time prolonged to 7 hours to obtain N1 -(tetrahydrofuranyl)-5-fluorouracil and N3 -(tetrahydrofuranyl)-5-fluorouracil in 1:1 molar ratio. The products were treated as described in the Example 4, then dissolved in toluene-ethyl acetate (1:1) mixture and subjected to chromatographic separation, which eluded at first 0.060 gr. (yield 30%) of N1 -substituted compound and then 0.050 gr. (yield 25%) of N3 -substituted compound.
EXAMPLE 16
The process of Example 15 was repeated with 0.13 gr. (1 mmol) of 2-acetoxytetrahydrofurane to obtain 0.058 gr. (yield 29%) of N1 -(tetrahydrofuranyl)-5-fluorouracil and 0.052 gr. (yield 26.0%) of N3 -(tetrahydrofuranyl)-5-fluorouracil.
EXAMPLE 17
The process of Example 15 was repeated with 0.10 gr. (1 mmol) of 2-methoxytetrahydrofurane to obtain 0.060 gr. (yield 30.0%) of N1 -(tetrahydrofuranyl)-5-fluorouracil and 0.052 gr. (yield 26.0%) of N3 -(tetrahydrofuranyl)-5-fluorouracil.
EXAMPLE 18
The process of Example 15 was repeated with 0.11 gr. (1 mmol) of 2-chlorotetrahydrofurane and without stannic chloride to obtain 0.064 gr. (yield 32.0%) of N1 -(tetrahydrofuranyl)-5-fluorouracil and 0.048 gr. (yield 24.0%) of N3 -(tetrahydrofuranyl)-5-fluorouracil.
EXAMPLE 19
The process of Example 15 was repeated with 0.24 gr. (1 mmol) of 2-(p-nitrobenzoyl)tetrahydrofurane to obtain 0.05 gr. (yield 29.5%) of N1 -(tetrahydrofuranyl)-5-fluorouracil and 0.052 gr. (yield 26.0%) of N3 -(tetrahydrofuranyl)-5-fluorouracil.
EXAMPLE 20
The process of Example 15 was repeated with 0.22 gr. (1 mmol) of 2-(p-tolylbenzoxy)-tetrahydrofurane to obtain 0.058 gr. (yield 29.0%) of N1 -(tetrahydrofuranyl)-5-fluorouracil and 0.050 gr. (yield 25.0%) of N3 -(tetrahydrofuranyl)-5-fluorouracil.
EXAMPLE 21
The process of Example 18 was repeated with 0.09 gr. (1 mmol) of 2-chlorotetrahydrofurane to obtain 0.062 gr. (yield 31.0%) of N1 -(tetrahydrofuranyl)-5-fluorouracil and 0.051 gr. (yield 25.5%) of N3 -(tetrahydrofuranyl)-5-fluorouracil.
EXAMPLE 22
The process of Example 15 was repeated but with a reaction time of 4 hours and with a reaction temperature of 20° C. to obtain 0.066 gr. (yield 33%) of N1 -(tetrahydrofuranyl)-5-fluorouracil and 0.046 gr. (yield 23%) of N3 -(tetrahydrofuranyl)-5-fluorouracil.
EXAMPLE 23
The process of Example 16 was repeated but with a reaction time of 4 hours and a reaction temperature of 20° C. to obtain 0.064 gr. (yield 32%) of N1 -(tetrahydrofuranyl)-5-fluorouracil and 0.046 gr. (yield 23%) of N3 -(tetrahydrofuranyl)-5-fluorouracil.
EXAMPLE 24
The process of Example 18 was repeated but with a reaction time prolonged to 7 hours to obtain 0.077 gr. (yield 30%) of N1 -(tetrahydrofuranyl)-5-bromouracil and 0.062 gr. (yield 24%) of N3 -(tetrahydrofuranyl)-5-bromouracil.
EXAMPLE 25
The process of Example 24 was repeated but with 0.13 gr. (1 mmol) of 2-acetoxytetrahydrofurane to obtain 0.075 gr. (yield 29%) of N1 -(tetrahydrofuranyl)-5-bromouracil and 0.064 gr. (yield 25%) of N3 -(tetrahydrofuranyl)-5-bromouracil.
EXAMPLE 26
9.6 gr. (0.05 mol) of 2-benzoxytetrahydrofurane and 17.7 gr. (0.025 mol) of bis(tri-n-butylstannyl)-5-fluorouracil obtained in the Example 1 were dissolved in 100 ml of dichloroethane, then added, at -5° to 0° C. and under agitation, with 13 gr. (0.05 mol) of stannic chloride and maintained at 0° to 5° C.
After 30 minutes, the reaction mixture was poured over a mixture of ice and sodium bicarbonate solution and extracted with chloroform. The extract was dried over anhydrous magnesium sulfate, concentrated under a reduced pressure and passed through a silica gel column to obtain 6.2 gr. (yield 91.8%) of N,N'-bis-(2'-tetrahydrofuranyl)-5-fluorouracil as an oily substance.
______________________________________                                    
Physical properties                                                       
______________________________________                                    
N.M.R. spectrum       δ 6.64, 1H                                    
                      J = 6 Hz                                            
                      δ 5.95, 1H                                    
                      J = 6 Hz                                            
______________________________________
EXAMPLE 27
The process of Example 26 was repeated but with 6.5 gr. (0.05 mol) of 2-acetoxytetrahydrofurane to obtain 6.0 gr. (yield 88.0%) of N,N'-bis-(2'-tetrahydrofuranyl)-5-fluorouracil.
EXAMPLE 28
5.5 gr. (0.05 mol) of 2-chlorotetrahydrofurane was dissolved in 100 ml of dichlorethane, to which 17.7 gr. (0.025 mol) of bis(tri-n-butylstannyl)-5-fluorouracil obtained in the Example 1 was added at -10° to 0° C. and under agitation. After 1 hour, the reaction mixture was poured over a mixture of ice and sodium bicarbonate solution, and extracted with chloroform. The extract was treated as described in the Example 26 to obtain 6.1 gr. (yield 90.3%) of N,N'-bis-(2'-tetrahydrofuranyl)-5-fluorouracil.
EXAMPLE 29
The process of Example 26 was repeated but with 5.3 gr. (0.05 mol) of 2-methoxytetrahydrofurane to obtain 6.0 gr. (yield 88.0%) of N,N'-bis(2'-tetrahydrofuranyl)-5-fluorouracil.
EXAMPLE 30
The process of Example 26 was repeated but with 9.6 gr. (0.05 mol) of 2-benzoxytetrahydrofurane and 14.2 gr. (0.02 mol) of bis(tri-n-butylstannyl)-5-fluorouracil to obtain 5.1 gr. (yield 95.0%) of N,N'-bis(2'-tetrahydrofuranyl)-5-fluorouracil.
EXAMPLE 31
The process of Example 26 was repeated but with 10.5 gr. (0.06 mol) of 2-benzoxytetrahydrofurane and 14.2 gr. (0.02 mol) of bis(tri-n-butylstannyl)-5-fluorouracil to obtain 5.0 gr. (yield 93.5%) of N,N'-bis-(2'-tetrahydrofuranyl)-5-fluorouracil.
EXAMPLE 32
The process of Example 26 was repeated but with a reaction time of 3 hours to obtain 5.6 gr. (yield 83.0%) of N,N'-bis-(2'-tetrahydrofuranyl)-5-fluorouracil.
EXAMPLE 33
The process of Example 26 was repeated but with a reaction time of 7 hours to obtain 5.1 gr. (yield 75.0%) of N,N'-bis(2'-tetrahydrofuranyl)-5-fluorouracil.
EXAMPLE 34
The process of Example 26 was repeated but with 15.8 gr. (0.025 mol) of bis(tri-n-propylstannyl)-5-fluorouracil to obtain 6.1 gr. (yield 90.3%) of N,N'-bis-(2'-tetrahydrofuranyl)-5-fluorouracil.
EXAMPLE 35
The process of Example 26 was repeated but with 10.5 gr. (0.06 mol) of 2-benzoxytetrahydrofurane and 23.5 gr. (0.04 mol) of bis(tri-n-butylstannyl)-5-fluorouracil to obtain 5.1 gr. (yield 47.0%) of N,N'-bis-(2'-tetrahydrofuranyl)-5-fluorouracil and 1.2 gr. (yield 14.5%) of N1 -(2'-tetrahydrofuranyl)-5-fluorouracil.
EXAMPLE 36
6.75 gr. (0.025 mol) of N,N'-bis-(2'-tetrahydrofuranyl)-5-fluorouracil was dissolved in 50 ml of methanol, and 2.48 gr. of boron trifluoride etherate at room temperature. After agitation for ca. 1 hour, the reaction mixture was poured over a mixture of ice and sodium bicarbonate solution and extracted with chloroform. The extract was dried over anhydrous magnesium sulfate and concentrated under a reduced pressure. After passing a silica gel column, the obtained product was recrystallized from ethanol to obtain 4.5 gr. (yield 90%) of N1 -(tetrahydrofuranyl)-5-fluorouracil.
EXAMPLE 37
6.75 gr. (0.025 mol) of N,N'-bis-(2'-tetrahydrofuranyl)-5-fluorouracil) was dissolved in 50 ml. of 1% methanolic solution of hydrochloric acid, then refluxed for ca. 10 minutes and cooled. After neutralization of hydrochloric acid, the reaction mixture was subjected to extraction, drying and recrystallization as described in the Example 36 to obtain 4.0 gr. (yield 80%) of N1 -(tetrahydrofuranyl)-5-fluorouracil.
EXAMPLE 38
9.6 gr. (0.05 mol) of 2-benzoxytetrahydrofurane and 17.7 gr. (0.025 mol) of bis(tri-n-butylstannyl)-5-fluorouracil obtained in the Example 1 were dissolved in 100 ml of dichlorethane, then added, at -5° to 0° C. and under agitation, with 13 gr. (0.05 mol) of stannic chloride and maintained at 0° to 5° C.
After 30 minutes the reaction mixture was poured over a mixture of ice and sodium bicarbonate solution and extracted with chloroform. The extract was dried over anhydrous magnesium sulfate and concentrated under a reduced pressure. The resulting oily substance was dissolved in 50 ml of methanol, then added with 2.48 gr. of boron trifluoride etherate at room temperature and stirred for ca. 1 hour. Successively the reaction mixture was poured over a mixture of ice and sodium bicarbonate solution and extracted with chloroform. The extract was dried over anhydrous magnesium sulfate and concentrated under a reduced pressure. After passing a silica gel column, the obtained product was recrystallized from ethanol to obtain 4.5 gr. (yield 90%) of N1 -(2'-tetrahydrofuranyl)-5-fluorouracil.
The above-mentioned oily substance was purified and identified as N,N'-bis-(2'-tetrahydrofuranyl)-5-fluorouracil.
______________________________________                                    
Physical properties                                                       
______________________________________                                    
N.M.R. spectrum       δ 6.64, 1H                                    
                      J = 6 Hz                                            
                      δ 5.95, 1H                                    
                      J = 6 Hz                                            
______________________________________
EXAMPLE 39
6.5 gr. (0.05 mol) of 2-acetoxytetrahydrofurane and 17.7 gr. (0.025 mol) of bis(tri-n-butylstannyl)-5-fluorouracil were dissolved, then added with 13 gr. (0.05 mol) of stannic chloride at -5° to 0° C. and under agitation, and maintained at 0° to 5° C.
After 1 hour, the reaction mixture was poured over a mixture of ice and sodium bicarbonate solution and extracted with chloroform. The extract was dried over anhydrous magnesium sulfate and concentrated under a reduced pressure. The resulting oily substance was dissolved in 50 ml of 1% methanolic solution of hydrochloric acid, refluxed for ca. 10 minutes, and cooled. After neutralization of hydrochloric acid, the reaction mixture was subjected to extraction, drying and recrystallization as described in the Example 7 to obtain 4.4 gr. (yield 88.0%) of N1 -(2'-tetrahydrofuranyl)-5-fluorouracil.
EXAMPLE 40
5.5 gr. (0.05 mol) of 2-chlorotetrahydrofurane was dissolved in 100 ml of dichlorethane, to which 17.7 gr. (0.025 mol) of bis(tri-n-butylstannyl)-5-fluorouracil obtained by the Example 1 was added at -10° to 0° C. and under agitation. After 1 hour the reaction mixture was poured over a mixture of ice and sodium bicarbonate solution and extracted with chloroform. The extract was treated as described in the Example 38 to obtain 4.6 gr. (yield 92.0%) of N1 -(tetrahydrofuranyl)-5-fluorouracil.
EXAMPLE 41
The process of Example 39 was repeated but with 5.3 gr. (0.05 mol) of 2-methoxytetrahydrofurane to obtain 4.4 gr. (yield 88.0%) of N1 -(2'-tetrahydrofuranyl)-5-fluorouracil.
EXAMPLE 42
The process of Example 39 was repeated but with 9.6 gr. (0.05 mol) of 2-benzoxytetrahydrofurane and 14.2 gr. (0.02 mol) of bis(tri-n-butylstannyl)-5-fluorouracil to obtain 3.8 gr. (yield 95.0%) of N1 -(2'-tetrahydrofuranyl)-5-fluorouracil.
EXAMPLE 43
The process of Example 39 was repeated but with 10.5 gr. (0.06 mol) of 2-benzoxytetrahydrofurane and 14.2 gr. (0.02 mol) of bis(tri-n-butylstannyl)-5-fluorouracil to obtain 3.7 gr. (yield 92.5%) of N1 -(2'-tetrahydrofuranyl)-5-fluorouracil.
EXAMPLE 44
The process of Example 38 was repeated but with a reaction time of 3 hours to obtain 4.2 gr. (yield 83.0%) of N1 -(2'-tetrahydrofuranyl)-5-fluorouracil.
EXAMPLE 45
The process of Example 38 was repeated but with a reaction time of 7 hours to obtain 3.8 gr. (yield 76.0%) of N1 -(2'-tetrahydrofuranyl)-5-fluorouracil.
EXAMPLE 46
The process of Example 38 was repeated but with 15.8 gr. (0.025 mol) of bis(tri-n-propylstannyl)-5-fluorouracil obtained in Example 3 to obtain 4.5 gr. (yield 90.0%) of N1 -(2'-tetrahydrofuranyl)-5-fluorouracil.
EXAMPLE 47
1.30 gr. (0.01 mol) of 5-fluorouracil and 5.96 gr. (0.01 mol) of bis(tri-n-butylstannyl)oxide were heated under reflux in 100 ml of toluene while water was continuously eliminated by distillation. After about 20 hours toluene was distilled off to obtain crude bis(tri-n-butylstannyl)-5-fluorouracil.
______________________________________                                    
Physical properties                                                       
______________________________________                                    
N.M.R. spectrum   ('H NMR):(CDCl.sub.3)                                   
                  δ H.sub.6 7.10 (d, J = 5Hz)                       
______________________________________
EXAMPLE 48
11.2 gr. (0.1 mol) of 2,4-dihydroxypyrimidine and 59.4 gr. (0.1 mol) of bis(tri-n-butylstannyl)oxide were refluxed in toluene with continuous elimination of formed water. After the completion of reaction the reaction mixture was concentrated to obtain 2,4-bis(tri-n-butylstannyl)pyrimidine in an approximately quantitative yield.
______________________________________                                    
Physical property                                                         
______________________________________                                    
Mass spectrum         M.sup.+ = 690                                       
______________________________________
EXAMPLE 49
The process of Example 1 was repeated with 12.7 gr. (0.1 mol) of 2-hydroxy-5-methyl-5-hydroxypyrimidine to obtain 2,4-bis(tri-n-butylstannyl)-5-methylpyrimidine in an approximately quantitative yield.
______________________________________                                    
Physical property                                                         
______________________________________                                    
N.M.R. spectrum   ('H N.M.R.)                                             
                  δ 6.87 (1H, S; H-6)                               
                  δ 1.88 (3H, S; C.sub.5 --CH.sub.3)                
______________________________________
EXAMPLE 50
The process of Example 47 was repeated with 19.1 gr. (0.1 mol) of 2-hydroxy-5-bromo-4-hydroxypyrimidine to obtain 2,4-bis(tri-n-butylstannyl)-5-bromopyrimidine in an approximately quantitative yield.
______________________________________                                    
Physical property                                                         
______________________________________                                    
N.M.R. spectrum  ('H N.M.R.):δ 7.30 (1H, S;                         
                 H-6)                                                     
______________________________________
EXAMPLE 51
The process of Example 47 was repeated with 12.8 gr. (0.1 mol) of 2-thio-4-hydroxyprimidine to obtain 2-thio(tri-n-butylstannyl)-4-tri-n-butylstannylpyrimidine in an approximately quantitative yield.
______________________________________                                    
        Physical property                                                 
______________________________________                                    
        δ 6.17 (1H, d, J = 6 Hz; H-5)                               
        δ 7.80 (1H, d, J = 6 Hz; H-6)                               
______________________________________

Claims (17)

What we claim is:
1. A process for producing pyrimidine nucleoside represented by the following general formula: ##STR6## wherein R stands for a hydrogen atom or a 2-tetrahydrofurane residue but both R's cannot simultaneously be hydrogen atoms, and Hal represents a fluorine atom, which comprises reacting bis(tri-lower alkylstannyl)-5-halogenouracil represented by the following general formula: ##STR7## wherein Alk stands for a lower alkyl radical and Hal has the same meaning as above; with 2-substituted tetrahydrofurane represented by the following general formula: ##STR8## wherein X stand for a halogen atom, a lower alkyloxy, lower aralkyloxy, lower alkylcarbonyloxy or arylcarbonyloxy radical; at a temperature within a range from -50° to 100° C.
2. A process according to the claim 1 wherein X is a benzoxy radical.
3. A process for producing N1 -(2'-tetrahydrofuranyl)-5-halogenouracil represented by the following general formula: ##STR9## wherein Hal stands for a fluorine atom, which comprises reacting bis(tri-lower alkylstannyl)-5-halogenouracil represented by the following general formula: ##STR10## , wherein Alk stands for a lower alkyl radical and Hal has the same meaning as above, with 2-substituted tetrahydrofurane represented by the following general formula: ##STR11## wherein X stands for a halogen atom, a lower alkyloxy, lower aralkyloxy, lower alkylcarbonyloxy or arylcarbonyloxy radical, with a molar ratio within a range of 1:1 to 1:1.5 in an organic solvent for 30 minutes to 3 hours at a temperature within a range from -50° to 100° C.
4. A process according to claim 3 wherein X is a benzoxy radical.
5. A process for producing N1 -(2'-tetrahydrofuranyl)-5-halogenouracil represented by the following general formula: ##STR12## wherein Hal stands for a fluorine atom, and N3 -(2'-tetrahydrofuranyl)-5-halogenouracil represented by the following general formula: ##STR13## wherein Hal has the same meaning as above, which comprises reacting bis(tri-lower alkylstannyl)-5-halogenuracil represented by the following general formula: ##STR14## wherein Alk stands for a lower alkyl radical and Hal has the same meaning as above, with 2-substituted tetrahydrofurane represented by the following general formula: ##STR15## wherein X stands for a halogen atom, a lower alkyloxy, lower aralkyloxy, lower alkylcarbonyloxy or arylcarbonyloxy radical, at a molar ratio within a range from 1:1 to 1:1.5; in an organic solvent for a period of 3 to 20 hours at a temperature within a range from -50° to 100° C. and separating thus resulting N1 -(2'-tetrahydrofuranyl)-5-halogenouracil and N3 -(2'-tetrahydrofuranyl)-5-halogenouracil.
6. A process according to claim 5 wherein X is a benzoxy radical.
7. A process for producing N1,N3 -bis(2'-tetrahydrofuranyl)-5-halogenouracil represented by the following general formula: ##STR16## wherein Hal stands for a fluorine atom, which comprises reacting bis(tri-lower alkylstannyl)-5-halogenouracil represented by the following general formula: ##STR17## wherein Alk stands for a lower alkyl radical and Hal has the same meaning as above; with 2-substituted tetrahydrofuran represented by the following general formula: ##STR18## wherein X is a halogen atom, a lower alkyloxy, lower aralkyloxy, lower alkylcarbonyloxy or arylcarbonyloxy radical; with a molar ratio higher than 1:2 in an organic solvent for a period longer than 1 hour at a temperature within a range from -50° to 100° C.
8. A process according to the claim 7 wherein X is a benzoxy radical.
9. A process for producing N1 -(2'-tetrahydrofuranyl)-5-halogenouracil represented by the following general formula: ##STR19## wherein Hal is a fluorine atom; which comprises reacting bis(tri-lower alkylstannyl)-5-halogenouracil represented by the following general formula: ##STR20## wherein Alk is a lower alkyl radical and Hal has the same meaning as above; with 2-substituted tetrahydrofurane represented by the following general formula: ##STR21## wherein X is a halogen atom, a lower alkyloxy, lower aralkyloxy, lower alkylcarbonyloxy or arylcarbonyloxy radical; with a molar ratio higher than 1:2 in an organic solvent at a temperature within a range from -50° to 100° C. and treating thus resulting reaction product with an acid.
10. A process according to the claim 9 wherein said acid is alcoholic solution of hydrochloric acid.
11. A process according to the claim 9 wherein said acid is etheric solution of boron trifluoride.
12. A process according to the claim 1 wherein said reaction is conducted in the presence of a Friedel-Crafts catalyst.
13. A process according to the claim 3 wherein the molar ratio is 1:1 to 1:1.2, the reaction is conducted in the presence of a Friedel-Crafts catalyst, and the temperature is from -5° to 30° C.
14. A process according to the claim 5 wherein the molar ratio is 1:1 to 1:1.2, the reaction is conducted in the presence of a Friedel-Crafts catalyst, and the temperature is from -5° to 30° C.
15. A process according to the claim 7 wherein the molar ratio is within a range from 1:2 to 1:3, the reaction is conducted in the presence of a Friedel-Crafts catalyst, the period is from 3 to 7 hours, and the temperature is from -5° to 30° C.
16. A process according to the claim 9 in which the acid is a Lewis acid.
17. A process according to the claim 9 wherein the acid is an inorganic acid.
US05/735,777 1975-12-04 1976-10-28 Novel process for producing pyrimidine nucleosides and novel pyrimidine nucleosides obtained thereby Expired - Lifetime US4324895A (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
JP50144637A JPS5268189A (en) 1975-12-04 1975-12-04 Preparation of pyrimidine-type nucleosides
JP50/144637 1975-12-04
JP18076A JPS5285178A (en) 1976-01-05 1976-01-05 Di(tri-lower-alkylstannyl)pyrimidine derivatives
JP51/180 1976-01-05
JP51/27837 1976-03-15
JP2783776A JPS52116483A (en) 1976-03-15 1976-03-15 Synthesis of pyrimidine nucleoside
JP2783676A JPS52111581A (en) 1976-03-15 1976-03-15 Synthesis of pyrimidine nucleoside
JP51/27836 1976-03-15
JP51/53463 1976-05-11
JP5346376A JPS5268190A (en) 1976-05-11 1976-05-11 Preparation of pyrimidine-type nucleosides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US06/287,642 Division US4447605A (en) 1975-10-24 1981-07-28 Di(tri-lower alkylstannyl)pyrimidine derivative and a process for producing the same

Publications (1)

Publication Number Publication Date
US4324895A true US4324895A (en) 1982-04-13

Family

ID=27517925

Family Applications (1)

Application Number Title Priority Date Filing Date
US05/735,777 Expired - Lifetime US4324895A (en) 1975-12-04 1976-10-28 Novel process for producing pyrimidine nucleosides and novel pyrimidine nucleosides obtained thereby

Country Status (1)

Country Link
US (1) US4324895A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110655507A (en) * 2018-06-29 2020-01-07 鲁南制药集团股份有限公司 Preparation method of antineoplastic drug tegafur

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3912734A (en) * 1972-11-20 1975-10-14 Solomon Aronovich Giller Method for preparing N{HD 1{B -(2{40 -furanidyl)-and N{HD 1{B -2(2{40 -pyranidyl) uracils
US3960864A (en) * 1974-05-06 1976-06-01 The University Of Utah Method of synthesizing 1-(tetrahydro-2-furanyl)-5-fluorouracil

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3912734A (en) * 1972-11-20 1975-10-14 Solomon Aronovich Giller Method for preparing N{HD 1{B -(2{40 -furanidyl)-and N{HD 1{B -2(2{40 -pyranidyl) uracils
US3960864A (en) * 1974-05-06 1976-06-01 The University Of Utah Method of synthesizing 1-(tetrahydro-2-furanyl)-5-fluorouracil

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110655507A (en) * 2018-06-29 2020-01-07 鲁南制药集团股份有限公司 Preparation method of antineoplastic drug tegafur
CN110655507B (en) * 2018-06-29 2022-10-18 鲁南制药集团股份有限公司 Preparation method of anti-tumor medicine tegafur

Similar Documents

Publication Publication Date Title
CA1334535C (en) 6-substituted acyclopyrimidine nucleoside derivative and antiviral agent containing the same as active ingredient thereof
IL32696A (en) Dihalopyrimidines and process for the preparation thereof
NO126322B (en)
US3868373A (en) 4-Amino-5-fluoro-2-tri(lower alkyl) silyloxypyrimidines
EP0193903B1 (en) Production of cytosine nucleosides
US5889013A (en) Pyrimidine acyclonucleoside derivatives
GB2125401A (en) Desoxyuridine derivatives and their use as pharmaceuticals
JP3884779B2 (en) Method for mass production of 2 ', 3'-didehydro-2', 3'-dideoxynucleosides
EP0080819B1 (en) 11-0-alkylerythromycin a derivatives
US4447605A (en) Di(tri-lower alkylstannyl)pyrimidine derivative and a process for producing the same
SU1240363A3 (en) Method of producing (e)-5-(2-vinyl bromide)uridine
DE3045375A1 (en) 5-Substd. pyrimidine nucleoside derivs. - useful as antiviral agents
US4324895A (en) Novel process for producing pyrimidine nucleosides and novel pyrimidine nucleosides obtained thereby
EP0061283A1 (en) Antiviral agents, their preparation and use
US4329460A (en) Uracil derivatives and production thereof
US3404144A (en) 1-beta-d-arabinofuranosyl-5-fluorocytosine compounds
KR880000704B1 (en) Preparation process for glylosidex
US4115642A (en) Method for preparing auranofin
US5717086A (en) Preparation of fluoro-nucleosides and intermediates for use therein
DE1943428C3 (en) Process for the preparation of pyrimidine and 6-azauracilnueleosides
US4159378A (en) Method for the preparation of derivatives of uracil
EP0049144B1 (en) 5-fluoro uracil derivatives
US3317532A (en) Derivatives of pyrimidine
EP0484843A1 (en) An optically active cyclobutyl pyrimidine
CA2012095C (en) 3'-tosylcytidine compounds and process for production thereof

Legal Events

Date Code Title Description
STCF Information on status: patent grant

Free format text: PATENTED CASE